Qlosi滴眼液的用法用量:用药指南,剂量调整,特殊人群用药

Qlosi eye drops were approved by the US FDA in October 2023 and need to be used under the guidance of a doctor.

Qlosi eye drops usage and dosage

1. Specific usage

Put one drop into each eye. To achieve effects lasting up to 8 hours, repeat eye drops for a second time 2-3 hours later.

2. Frequency of medication

It can be used daily or as needed, up to twice a day.

3. Interval administration

If multiple topical ophthalmic drugs are used at the same time, there must be an interval of at least 5 minutes between administration of different drugs.

4. Drug overdose

Systemic toxic reactions after topical use of Qlosi eye drops are rare, but sensitive patients may occasionally experience sweating and gastrointestinal hyperfunction.

Accidental ingestion can cause sweating, salivation, nausea, tremors, slowed pulse and decreased blood pressure.

For moderate overdose, spontaneous recovery is expected and may be assisted by intravenous fluids to correct dehydration. Atropine, the pharmacological antagonist of pilocarpine, should be used in patients exhibiting severe intoxication.

The pictures come from public channels (such as the official website of the FDA, the official website of the original drug manufacturer, etc.) and are for reference only.

Qlosi Eye Drops Medication for Special Populations

1. Pregnancy

There are currently no adequate and well-controlled studies on the use of Qlosi Eye Drops in pregnant women to inform drug-related risks. Oral pilocarpine was administered to pregnant rats during the organogenesis and lactation periods, and no adverse effects occurred at clinically relevant doses.

2. Lactation period

There is no data on the presence of pilocarpine in human milk, its impact on breast-fed infants, or its effect on milk secretion. It is impossible to tell the risk of Qlosi eye drops to lactating infants. Following a single oral administration, pilocarpine and/or its metabolites are excreted in the milk of lactating rats.

Systemic exposure to pilocarpine after topical ocular administration is low, and it is unknown whether measurable levels of pilocarpine will be present in breast milk following ocular use of Qlosi eye drops.

The developmental and health benefits of breastfeeding should be considered, along with the mother's clinical need for Qlosi Eye Drops and any potential adverse effects of Qlosi Eye Drops on the breastfed child.

3. Pediatric use

Presbyopia is an age-related disease that does not occur in the pediatric population.

4. Geriatric use

Clinical studies of Qlosi eye drops did not include subjects aged 65 and above to determine whether their reactions were different from younger subjects. Safety and effectiveness in patients over 65 years of age have not been established.

Qlosi Eye Drops Storage

Qlosi Eye Drops should be stored refrigerated at 36°F to 46°F (2°C to 8°C). Once the foil pouch is opened, the single-dose vial may be stored at room temperature [up to 77°F (25°C)] and used within 30 days. Store unused product away from light and discard opened vials after use.